Dabigatran: ready for prime time?

Article Details

Citation

Copy to clipboard

Karthikeyan G, Eikelboom JW, Hirsh J

Dabigatran: ready for prime time?

Pol Arch Med Wewn. 2010 Apr;120(4):137-42.

PubMed ID

20424539 [ View in PubMed

]

Abstract

Studies in high-risk surgical patients have demonstrated the efficacy of the selective inhibitors of factor Xa and thrombin in preventing venous thromboembolism. Because of their predictable dose-response, which eliminates the need for routine laboratory monitoring, they may be more convenient for patients requiring long-term therapy, and have the potential to improve the quality of anticoagulation. The results from 2 large trials of dabigatran (a thrombin inhibitor) compared to warfarin, in patients with atrial fibrillation and those with acute symptomatic venous thromboembolism, have recently become available. These trials provide convincing evidence of the efficacy of dabigatran in preventing patient-important clinical outcomes when compared to warfarin. In this paper we critically review these trials and discuss the feasibility of replacing warfarin with dabigatran for these indications.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Dabigatran etexilate	Prothrombin	Protein	Humans	Yes	Inhibitor	Details